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Background: B-type natriuretic peptide (BNP) is used widely to exclude heart failure (HF) in patients with dyspnea when BNP < 100 pg/ml. 
However, most studies of BNP have focused on diagnosing HF with reduced ejection fraction (EF) and the utility of BNP in patients with HF and 
preserved EF (HFpEF) is less clear. We hypothesized that BNP < 100 pg/ml does not reliably exclude HFpEF, a heterogeneous disorder commonly 
associated with obesity.
Methods: We prospectively studied 151 consecutive patients enrolled in the Northwestern University HFpEF Program (mean age 65±12 years, 
60% female). All subjects met Framingham criteria for HF and had EF≥50%. Patients with pericardial disease, greater than moderate valvular 
disease, and pulmonary arterial hypertension were excluded. We measured BNP and performed invasive hemodynamic testing in all patients. Clinical 
characteristics and hemodynamics were compared between HFpEF patients with normal (< 100 pg/ml) vs. elevated (> 100 pg/ml) BNP. Patients 
were followed for cardiovascular (CV) hospitalization and death for 1 year after entry into the study.
Results: All patients had elevated left ventricular end-diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) ≥ 15 mmHg at 
the time of invasive hemodynamic testing, confirming the diagnosis of HFpEF. Of the 151 patients, 44 (29%) had BNP < 100 pg/ml. Subjects with 
normal BNP were younger (61±11 vs. 67±12 years, p=0.012) and more obese (43% vs 22% with BMI ≥ 35 kg/m2, p=0.008). Mean NYHA class was 
lower in patients with normal BNP (2.4±0.8 vs. 2.2±0.6), although this did not reach statistical significance (p=0.14). Patients with normal BNP also 
had less severe hemodynamic abnormalities (e.g., PCWP 21±5 mmHg vs 24±7 mmHg, p=0.04). After adjustment for age, sex, and BMI, a BNP < 100 
pg/ml was associated with a reduced odds ratio of 0.27 (95% CI 0.08-0.89, p=0.032) for the combined end-point of CV hospitalization and death 
after 1 year of follow-up.
Conclusion: In patients with confirmed HFpEF, 29% had BNP < 100 pg/ml. A normal BNP does not excluded HFpEF, especially in obese patients. 
However, a normal BNP is associated with less severe hemodynamic derangements and may be associated with a better prognosis.
